[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"secondary-progress-multiple-sclerosis-spms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:secondary-progress-multiple-sclerosis-spms":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100656495","phase-1-a-study-of-c-car168-in-participants-with-progressive-multiple-sclerosis-100656495",false,"NCT07825389","C-CAR168, an Autologous Anti-CD20\u002FBCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy","Multi-center, Phase 1b\u002F2 Clinical Study of an Autologous Anti-CD20\u002FBCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy","Key Inclusion Criteria:\n\n* Able to sign and date the informed consent form.\n* Male or female, 18-55 years of age, body weight \\>=40 kg.\n* Diagnosis of MS according to the 2024 McDonald criteria with cohort-specific progressive MS requirements.\n* Cohort 1: active SPMS; Cohort 2: PPMS or non-active SPMS.\n* Inadequate response to at least one prior high-efficacy disease-modifying therapy administered for at least 6 months.\n* Documented disability progression over the prior 24 months.\n* EDSS 3.0 to 6.5, inclusive.\n* Meets protocol-defined disease-duration, CSF, organ-function, cardiac\u002Fpulmonary, pregnancy testing, contraception, vaccination, and cellular-therapy follow-up requirements.\n\nKey Exclusion Criteria\n\n* RRMS, clinically isolated syndrome, radiologically isolated syndrome, or another diagnosis better explaining the neurologic course.\n* Alternative inflammatory demyelinating disorders, including AQP4-antibody-positive NMOSD and MOG-antibody-associated disease.\n* Active or chronic infection requiring antibiotics, or protocol-specified positive infectious disease testing.\n* Inadequate washout from prior MS therapy or specified recent immunomodulatory treatments.\n* Prior CAR T-cell therapy, other genetically modified immune cell therapy, or gene therapy.\n* Pregnant or breastfeeding, or planning pregnancy during the protocol-defined follow-up period.\n* Specified major cardiovascular, neurologic, transplant, malignancy, bleeding\u002Fthromboembolic, allergy, or protocol-compliance exclusions.","ALL","18 Years","55 Years",{"count":20,"type":21},119,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a global, multicenter, Phase 1b\u002F2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20\u002FBCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).",[28,29,30,31,32,33,34,35,36],"Multiple Sclerosis","Primary Progressive Multiple Sclerosis","Secondary Progress Multiple Sclerosis (SPMS)","Primary Progressive Multiple Sclerosis (PPMS)","MS","MS (Multiple Sclerosis)","Neuro-Degenerative Disease","Neuro-Degenerative Diseases","Autoimmune",[38,39,40,41,42,43,44,45,29,46,47,48,36,49,50,51],"Progressive Multiple Sclerosis","SPMS","PPMS","CAR T-Cell Therapy","C-CAR168","CD20","BCMA","Secondary Progressive Multiple Sclerosis","CAR-T","CAR T cell","CAR T","neurodegenerative","chimeric antigen receptor T cell","Refractory","NOT_YET_RECRUITING","2026-10-07",{"date":55,"type":56},"2026-10-13","ACTUAL",{"date":58,"type":21},"2027-02",{"date":60,"type":21},"2030-02",{"name":62,"class":63},"AbelZeta Inc.","INDUSTRY",2]